By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
MedsparkMedsparkMedspark
  • Home
  • News & Alerts
    News & AlertsShow More
    Ohio State and Microsoft build a hospital that senses itself
    By
    msadmin
    November 11, 2026
    Charta raises $55M to settle claims before doctors bill
    By
    msadmin
    November 11, 2026
    Oura spends $625M to put doctors behind its ring
    By
    msadmin
    November 11, 2026
    Google puts an agent layer under every hospital workflow
    By
    msadmin
    November 11, 2026
    XtalPi hands Pierre Fabre a molecule factory for stubborn cancer targets
    By
    msadmin
    November 10, 2026
  • Spotlight
    SpotlightShow More
    Robinhood Ventures Fund II brings retail capital to healthcare AI
    By
    msadmin
    August 13, 2026
    Adialante brings accessible MRI-based cancer screening
    By
    msadmin
    August 11, 2026
    CellType models biology so AI can discover drugs
    By
    msadmin
    August 11, 2026
    Healthcare AI startups in Robinhood Ventures Fund II
    By
    msadmin
    August 11, 2026
    OpenAI launches GPT-Rosalind for life sciences research
    By
    msadmin
    July 17, 2026
  • Articles
    ArticlesShow More
    Singapore clinics let an AI watch for referrals nobody ever sent
    By
    msadmin
    November 1, 2026
    An AI team of agents grades immunotherapy side effects
    By
    msadmin
    October 30, 2026
    Brain implant decoders fail when patients or hardware change, review warns
    By
    msadmin
    October 25, 2026
    Proteomics model picks breast cancer drugs from biopsies
    By
    msadmin
    September 10, 2026
    CRISP model reads frozen sections to steer cancer surgery
    By
    msadmin
    September 10, 2026
  • About
    • Mission
    • Services
    • Contact
  • Shop
    • All Items
    • By Category
    • Cart
  • Newsletter
Font ResizerAa
MedsparkMedspark
Font ResizerAa
  • Home
  • News & Alerts
  • Spotlight
  • Articles
  • About
  • Shop
  • Newsletter
  • Home
  • News & Alerts
  • Spotlight
  • Articles
  • About
    • Mission
    • Services
    • Contact
  • Shop
    • All Items
    • By Category
    • Cart
  • Newsletter
Follow US
News & Alerts

Brainomix finds a routine CT signal for stroke drug responders

A post-hoc look at the CHARM trial suggests standard non-contrast CT, read by AI, can sort severe stroke patients by who benefits from Remedy's glyburide therapy.

MedSpark Staff
By
msadmin
MedSpark Staff
Bymsadmin
Medical, Healthcare, & Biotech/Pharma AI News
Follow:
Published: October 29, 2026
Share
2 Min Read
SHARE

Brainomix presented findings at the World Stroke Conference in Seoul suggesting that automated analysis of ordinary non-contrast CT can help pick out severe stroke patients more likely to respond to an experimental drug.

Contents
Sizing the infarct from the scan most hospitals haveWhat it means for trial design

The Oxford spinout worked with Remedy Pharmaceuticals on a post-hoc analysis of the Phase 3 CHARM trial, which tested intravenous glyburide, or CIRARA, in large hemispheric infarction, one of the most disabling forms of stroke.

Sizing the infarct from the scan most hospitals have

Earlier looks at CHARM hinted that patients with smaller imaging-defined infarct cores did better. Those measures leaned on CT perfusion and MRI, modalities that many emergency departments cannot run around the clock.

Brainomix instead used its 360 Stroke software and in-house AI Core Lab to measure acute infarct volume from non-contrast CT in 428 patients, then compared that with outcomes.

In a per-protocol group of 362 patients, CIRARA showed a borderline association with better scores on the modified Rankin Scale. Among 191 patients whose core volume sat below 125 mL, the link became significant, including a greater likelihood of reaching mRS 0 to 3 at 90 days.

What it means for trial design

George Harston, Brainomix’s chief medical and innovation officer, said the appeal is access: if selection works on the most widely available stroke scan, trials can run at far more hospitals.

The caveats are substantial. CHARM was terminated early after sponsor Biogen pulled back, and the program has since returned to Remedy. Post-hoc subgroup findings are hypothesis-generating, not proof.

Remedy CEO Sven Jacobson called the signals encouraging and said the company intends to investigate them further.

TAGGED:BrainomixCIRARAclinical trialsMedical Imaging AIPatient selectionRemedy PharmaceuticalsStroke AI
SOURCES:PR Newswire
Share This Article
Facebook Copy Link Print
MedSpark Staff
Bymsadmin
Follow:
Medical, Healthcare, & Biotech/Pharma AI News

You Might Also Like

News & Alerts

Otter Health lands $8M to fight prior authorization with AI

By
msadmin
October 15, 2026
News & Alerts

AI nutrition duo merges to chase insured GLP-1 weight care

By
msadmin
August 25, 2026
News & Alerts

PointCaré Raises €1.5M to Bring Real-Time AI Decision Support to Critical Care

By
Yu Chi Huang
June 19, 2025
News & Alerts

Lyric acquires Concert to expand AI precision medicine payments

By
msadmin
July 17, 2026

AI news, analysis, and insights for healthcare, biotech, and pharma.

Facebook Twitter Youtube Linkedin
Quick Links
  • News & Alerts
  • Articles
  • Spotlight
  • Events
About Medspark
  • Mission
  • Services
  • Contact

© Copyright 2026 MedSpark. All rights reserved.

Privacy Policy | Legal